Drug Target Review

NOVEMBER 8, 2023

Problem w/ CTs and foundational understanding of Vittoria: can you explore the current limitations of cell therapies and the challenges faced by patients and providers? Currently, only a small percentage of cancers can be effectively treated with cell therapies, and there is little diversity in the currently approved products.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Medical Schools Regulations 59

Drug Target Review

JULY 1, 2024

Could you elaborate on the potential market size for SRP-001 and how it fits into the broader landscape of pain therapies? With a strong market entry strategy and continuous evidence generation, SRP-001 has the potential to transform pain therapy and meet the enormous unmet needs in this field. South Rampart Pharma, Inc.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Drug Target Review

MARCH 15, 2024

He has a post-doctorate in virology, viral pathogenesis, viral vector development, and vaccines evaluation from Harvard Medical School, and a PhD in virology/molecular biology. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. References Mistry RK, Kelsall E, Sou SN, et al. Biotechnol Prog.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

Broad Institute

JUNE 21, 2023

said Vamsi Mootha , senior author of the study, an institute member at the Broad, professor of systems biology and medicine at Harvard Medical School, and professor of molecular biology at Massachusetts General Hospital.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Codon

JUNE 26, 2023

Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. Nevertheless, phage therapy did have a stint in the U.S. I’ll post an update soon. coli in mice.

DNA 52

DNA Therapies Engineering Clinical Trials 52